CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Stock issuance expenses	$ 92,648	$ 97,260
Warrant exercise costs	393,285	0
Series D Convertible Preferred Stock
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment	$ 488,270
Series C Convertible Preferred Stock
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment		$ 235,640